$ICCC

te Boekhorst Paul Francis Olivier purchased $76K of ICCC

te Boekhorst Paul Francis Olivier (President and CEO) purchased 8,000 shares of IMMUCELL CORP /DE/ (ICCC) at $9.50 on 2026-06-18.

Original reporting
SEC EDGAR · te Boekhorst Paul Francis Olivier
Published Jun 22, 2026, 4:00 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 6, 2026, 6:39 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$ICCC
Bullish
medium confidence
Mentioned
$ICCC
Relevance
4/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ICCCBullishLow
01

Why it matters

This provides a fresh, primary-source datapoint of insider buying (8,000 shares) but does not include any new company-specific fundamentals such as earnings, guidance, contracts, or regulatory actions.

02

Market read

Traders may treat the filing as a mild sentiment input, but it is unlikely to drive a major repricing without accompanying fundamental catalysts.

03

What to watch

The article does not state option exercises, tax considerations, or whether the CEO has a history of similar buying, limiting inference from this one trade.

Relevance 4/10Novelty 3/10Timing: filed 2026-06-22, transaction dated 2026-06-18

Background

The article is an SEC Form 4 insider transaction disclosure for IMMUCELL CORP, filed by the company’s President and CEO.

Company-level read

Ticker impact

$ICCCBullishMedium confidence
Context

IMMUCELL CORP CEO bought 8,000 shares at $9.4950/share via an open-market purchase disclosed on Form 4.

Expected impact

Likely modest, short-lived sentiment lift at most; no clear catalyst for a sustained move.

Evidence & confidence

Form 4 shows a direct open-market purchase by the CEO, but the article provides no new operational, financial, or regulatory development beyond the transaction details.

Market effects

No sector-level read-through; this is a single-company insider transaction.

None indicated.

None indicated.

Counterpoint

Insider purchases can be routine or planned; without a 10b5-1 plan, it still may reflect diversification or compensation timing rather than a strong fundamental view.

Key entities

  • IMMUCELL CORP /DE/

    Subject of the Form 4 insider transaction disclosure.

  • te Boekhorst Paul Francis Olivier

    President and CEO who reported the open-market purchase.

Related articles

$ICCCMed

ImmuCell Announces a 12% Increase in Product Sales in Q2 of 2026 and a 21% Increase in the First Six Months of 2026, Based on Preliminary, Unaudited Sales Results

ImmuCell (Nasdaq: ICCC) reported preliminary, unaudited sales for Q2 2026. Total product sales were $7.2 million, up 11.5% year over year, with domestic sales up 27.7% and international down 38.9%. For the first six months, sales rose 20.9% to $17.5 million. Management will discuss results on Aug. 14, 2026.